VIDEO: SGLT2 inhibitors show promise in nondiabetic kidney disease
In a video, Linda F. Fried, MD, MPH, FASN, of University of Pittsburgh, VA Pittsburgh Healthcare System, and co-chair of ASN Kidney Week Education Committee, discussed results of a subanalysis from the DAPA-CKD trial presented at ASN Kidney Week.
Dapagliflozin, an SGLT2 inhibitor, slowed progression of chronic kidney disease and decreased all-cause mortality in CKD patients, with similar effects in patients with and without diabetes, according to Fried.
“Though the mechanisms are not 100% clear, it looks like in those with proteinuric kidney disease of any etiology that we have another medication can decrease cardiovascular events and can slow progression of kidney disease,” she said.
Fried also discussed the ongoing EMPA-Kidney study investigating empagliflozin, also a SGLT2 inhibitor, to reduce the risks for renal disease progression and cardiovascular death, which shows promise as another emerging treatment for nondiabetic kidney disease.
Collapse
Wheeler D, et al. #FR-OR58. Presented at: ASN Kidney Week. Oct. 22-25, 2020 (virtual meeting).
Read more about